Kohji Takemura, MD· @KohjiToncol · X·· 2 天前评分70
正文 · 机器翻译
KEYNOTE-905 预设分析：
EV + pembrolizumab vs 仅 pembrolizumab 提示，EV 在新辅助治疗中发挥着关键作用。
但在辅助治疗中真的有必要使用 EV 吗？
希望 VOLGA 明天能提供一些线索！
#ESMO26
229 浏览 · 1 赞 · 2 转发 · 0 回复
会议摘要
4733O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905
https://esmocongress.esmo.orgNCT03924895NCT03924895按 - **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) 对上
- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
https://esmocongress.esmo.org来源：Kohji Takemura, MD · x.com